This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Neal L. Benowitz, MD

JAMA. 1991;266(22):3174-3177.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

CIGARETTE smoking is a major preventable cause of fetal death and injury, yet many women continue to smoke cigarettes throughout pregnancy. The most effective pharmacologic adjunct to smoking cessation therapy is nicotine replacement, including nicotine chewing gum or transdermal nicotine. However, the use of nicotine replacement therapy is contraindicated during pregnancy. The analysis presented herein suggests that the benefits of nicotine replacement therapy to aid smoking cessation in pregnant women who cannot stop smoking without such therapy substantially outweigh the risks of continued smoking or the risks of nicotine replacement per se.

PREVALENCE OF CIGARETTE SMOKING DURING PREGNANCY

Although the prevalence of smoking has declined in recent years and many women quit smoking when they become pregnant, 20% to 25% of pregnant American women continue to smoke throughout pregnancy; many of these women are heavy smokers. The National Health Interview survey of women pregnant in 1985 or with a birth . . . [Full Text PDF of this Article]

Author Affiliations
From the Departments of Medicine, Psychiatry, and Pharmacy, University of California, San Francisco, and the Division of Clinical Pharmacology and Experimental Therapeutics, San Francisco General Hospital Medical Center.

Footnotes
This report was submitted to the Food and Drug Administration Drugs of Abuse Advisory Committee, May 8, 1991. The opinions expressed are those of the author and do not necessarily reflect those of the Food and Drug Administration.

Reprint requests to the Division of Clinical Pharmacology and Experimental Therapeutics, San Francisco General Hospital Medical Center, 1011 Potrero Ave, Bldg 30, 5th Floor, San Francisco, CA 94110 (Dr Benowitz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?